During the past decade, Hopital Europeen Georges Pompidou; Service D'Oncologie Medicale conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 5 clinical trials were completed, i.e. on average, 55.6% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 2 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hopital Europeen Georges Pompidou; Service D'Oncologie Medicale" #1 sponsor was "Hoffmann-La Roche" with 8 trials, followed by "Assistance Publique - Hôpitaux de Paris" with 2 trials sponsored, "Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie" with 2 trials sponsored, "G1 Therapeutics, Inc." with 1 trials sponsored and "Pfizer" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hopital Europeen Georges Pompidou; Service D'Oncologie Medicale" #1 collaborator was "ARTIC group (oncologists and urologists association)" with 1 trials as a collaborator, "Chugai" with 1 trials as a collaborator, "Exelixis" with 1 trials as a collaborator and "Hospira, now a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Hopital Europeen Georges Pompidou; Service D'Oncologie Medicale" are "Bladder Cancer" (2 trials), "Renal Cell Carcinoma" (2 trials), "Urothelial Carcinoma" (2 trials), "Adenocarcinoma of the Prostate" (1 trials) and "Carcinoma, Renal Cell" (1 trials). Many other conditions were trialed in "Hopital Europeen Georges Pompidou; Service D'Oncologie Medicale" in a lesser frequency.

Most popular intervention types in "Hopital Europeen Georges Pompidou; Service D'Oncologie Medicale" are "Drug" (12 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (4 trials), "Sunitinib" (3 trials), "Bevacizumab" (2 trials), "Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody" (1 trials) and "Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hopital Europeen Georges Pompidou; Service D'Oncologie Medicale" are 11 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Hopital Europeen Georges Pompidou; Service D'Oncologie Medicale". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Hopital Europeen Georges Pompidou; Service D'Oncologie Medicale, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Hopital Europeen Georges Pompidou; Service D'Oncologie Medicale, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".